Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 13, Issue 577, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aba7401
Keywords
-
Categories
Funding
- Cancer Council of Western Australia [APP1129386]
- Cancer Australia [APP1101390, APP1147153]
- Telethon-Perth Children's Hospital Research Fund
- Kids Cancer Project
- Cure Brain Cancer Foundation
- Perth Children's Hospital Foundation
- Pirate Ship Foundation
- NIH/NCI [CA-09832, CA-02165]
- American Lebanese Syrian Associated Charities
- NCI [R01-CA159859, P30-CA30199]
- William's Superhero Fund
- McDowell Charity Trust
- John Lillie Cancer Research Fellowship
- Brainchild Fellowship
- Cancer Council of Western Australia Fellowship
- Stan Perron Chair of Paediatric Haematology and Oncology
- Australian Government
Ask authors/readers for more resources
The study found that CHK1/2 inhibition can enhance the cytotoxic activity of multiple chemotherapy drugs, reduce tumor burden, increase survival in medulloblastoma, and validated the clinical effectiveness in different subgroups.
Medulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine. To identify the best-in-class inhibitor, multiple CHK1/2 inhibitors were assessed in mice bearing intracranial MB. When combined with DNA-damaging chemotherapeutics, CHK1/2 inhibition reduced tumor burden and increased survival of animals with high-risk MB, across multiple different models. In total, we tested 14 different models, representing distinct MB subgroups, and data were validated in three independent laboratories. Pharmacodynamics studies confirmed central nervous system penetration. In mice, combination treatment significantly increased DNA damage and apoptosis compared to chemotherapy alone, and studies with cultured cells showed that CHK inhibition disrupted chemotherapy-induced cell cycle arrest. Our findings indicated CHK1/2 inhibition, specifically with LY2606368 (prexasertib), has strong chemosensitizing activity in MB that warrants further clinical investigation. Moreover, these data demonstrated that we developed a robust and collaborative preclinical assessment platform that can be used to identify potentially effective new therapies for clinical evaluation for pediatric MB.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available